Table 1.
Baseline characteristics of patients who were exposed to rituximab and those who were Rituximab naïve.
| Patient Characteristics | Rituximab n=69 | Rituximab Naïve n=41 |
|---|---|---|
| Sex | ||
| Male | 43 | 27 |
| Female | 26 | 14 |
| Age at diagnosis | ||
| Median | 52 years | 46 years |
| Range | 24–69 | 24–64 |
| Stage at Diagnosis (%) | ||
| (I,II) | 36% | 29% |
| (III/IV) | 64% | 71% |
| Histology (%) | ||
| DLBCL | 81% | 98% |
| DLBCL- T Cell rich B cell | 9% | 2% |
| DLBCL- follicular grade 3 | 10% | 0% (p=0.01) |
| # Pre-transplant salvage regimens | ||
| Mean | 1.4 | 1.3 |
| Range | 1–5 | 1–4 |
| Pretransplant disease status (%) | ||
| Complete Remission | 56% | 32% (p=0.07) |
| Partial Response | 35% | 41% |
| Conditioning Regimen (%) | ||
| CBV | 95% | 76% |
| Cy/TBI | 1% | 18% |
| BEAC or BEAM | 4% | 6% |
DLBCL: Diffuse Large B cell lymphoma, CBV: cyclophosphamide, BCNU and etoposide, Cy/TBI: Cytoxan/Total body radiation, BEAC: BCNU, etoposide, ARA-C, cyclophosphamide, BEAM: BCNU, etoposide, ARA-C and melphalan